Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
C/EBPβ is a MYB- and p300-cooperating pro-leukemogenic factor and promising drug target in acute myeloid leukemia.
Yusenko MV, Trentmann A, Casolari DA, Abdel Ghani L, Lenz M, Horn M, Dörner W, Klempnauer S, Mootz HD, Arteaga MF, Mikesch JH, D'Andrea RJ, Gonda TJ, Müller-Tidow C, Schmidt TJ, Klempnauer KH. Yusenko MV, et al. Among authors: mikesch jh. Oncogene. 2021 Jul;40(29):4746-4758. doi: 10.1038/s41388-021-01800-x. Epub 2021 May 6. Oncogene. 2021. PMID: 33958723 Free PMC article.
MYST2 acetyltransferase expression and Histone H4 Lysine acetylation are suppressed in AML.
Sauer T, Arteaga MF, Isken F, Rohde C, Hebestreit K, Mikesch JH, Stelljes M, Cui C, Zhou F, Göllner S, Bäumer N, Köhler G, Krug U, Thiede C, Ehninger G, Edemir B, Schlenke P, Berdel WE, Dugas M, Müller-Tidow C. Sauer T, et al. Among authors: mikesch jh. Exp Hematol. 2015 Sep;43(9):794-802.e4. doi: 10.1016/j.exphem.2015.05.010. Epub 2015 Jun 11. Exp Hematol. 2015. PMID: 26072331 Free article.
Ciprofloxacin versus colistin prophylaxis during neutropenia in acute myeloid leukemia: two parallel patient cohorts treated in a single center.
Pohlen M, Marx J, Mellmann A, Becker K, Mesters RM, Mikesch JH, Schliemann C, Lenz G, Müller-Tidow C, Büchner T, Krug U, Stelljes M, Karch H, Peters G, Gerth HU, Görlich D, Berdel WE. Pohlen M, et al. Among authors: mikesch jh. Haematologica. 2016 Oct;101(10):1208-1215. doi: 10.3324/haematol.2016.147934. Epub 2016 Jul 28. Haematologica. 2016. PMID: 27470601 Free PMC article.
A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia.
Schliemann C, Gerss J, Wiebe S, Mikesch JH, Knoblauch N, Sauer T, Angenendt L, Kewitz T, Urban M, Butterfass-Bahloul T, Edemir S, Vehring K, Müller-Tidow C, Berdel WE, Krug U. Schliemann C, et al. Among authors: mikesch jh. PLoS One. 2016 Oct 7;11(10):e0164499. doi: 10.1371/journal.pone.0164499. eCollection 2016. PLoS One. 2016. PMID: 27716819 Free PMC article. Clinical Trial.
Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML).
Kessler T, Koschmieder S, Schliemann C, Crysandt M, Mikesch JH, von Stillfried S, Stelljes M, Pohlen M, Lenz G, Kirsch A, Vehring K, Wardelmann E, Hartmann W, Bormann E, Gerss J, Brümmendorf TH, Müller-Tidow C, Berdel WE. Kessler T, et al. Among authors: mikesch jh. Ann Hematol. 2019 Jun;98(6):1393-1401. doi: 10.1007/s00277-019-03651-9. Epub 2019 Mar 21. Ann Hematol. 2019. PMID: 30903275 Clinical Trial.
The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia.
Angenendt L, Bormann E, Pabst C, Alla V, Görlich D, Braun L, Dohlich K, Schwöppe C, Bohlander SK, Arteaga MF, Wethmar K, Hartmann W, Angenendt A, Kessler T, Mesters RM, Stelljes M, Rothenberg-Thurley M, Spiekermann K, Hébert J, Sauvageau G, Valk PJM, Löwenberg B, Serve H, Müller-Tidow C, Lenz G, Wörmann BJ, Sauerland MC, Hiddemann W, Berdel WE, Krug U, Metzeler KH, Mikesch JH, Herold T, Schliemann C. Angenendt L, et al. Among authors: mikesch jh. Leukemia. 2019 Dec;33(12):2830-2841. doi: 10.1038/s41375-019-0505-x. Epub 2019 Jun 10. Leukemia. 2019. PMID: 31182782
Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?
Röllig C, Kramer M, Schliemann C, Mikesch JH, Steffen B, Krämer A, Noppeney R, Schäfer-Eckart K, Krause SW, Hänel M, Herbst R, Kunzmann V, Einsele H, Jost E, Brümmendorf TH, Scholl S, Hochhaus A, Neubauer A, Sohlbach K, Fransecky L, Kaufmann M, Niemann D, Schaich M, Frickhofen N, Kiani A, Heits F, Krümpelmann U, Kaiser U, Kullmer J, Wass M, Stölzel F, von Bonin M, Middeke JM, Thiede C, Schetelig J, Berdel WE, Ehninger G, Baldus CD, Müller-Tidow C, Platzbecker U, Serve H, Bornhäuser M. Röllig C, et al. Among authors: mikesch jh. Blood. 2020 Aug 13;136(7):823-830. doi: 10.1182/blood.2019004583. Blood. 2020. PMID: 32496541 Free article.
A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy.
Wass M, Göllner S, Besenbeck B, Schlenk RF, Mundmann P, Göthert JR, Noppeney R, Schliemann C, Mikesch JH, Lenz G, Dugas M, Wermke M, Röllig C, Bornhäuser M, Serve H, Platzbecker U, Foerster KI, Burhenne J, Haefeli WE, Müller LP, Binder M, Pabst C, Müller-Tidow C; Study Alliance Leukemia (SAL). Wass M, et al. Among authors: mikesch jh. Leukemia. 2021 Mar;35(3):701-711. doi: 10.1038/s41375-020-0892-z. Epub 2020 Jun 19. Leukemia. 2021. PMID: 32561840 Free PMC article. Clinical Trial.
73 results